UK Markets close in 4 hrs 11 mins

Frequency Therapeutics, Inc. (FREQ)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.1100-0.1600 (-12.60%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.2700
Open1.2800
Bid1.0900 x 21500
Ask1.1100 x 1800
Day's range1.0700 - 1.2800
52-week range1.0700 - 10.9000
Volume1,044,038
Avg. volume746,339
Market cap38.409M
Beta (5Y monthly)0.62
PE ratio (TTM)N/A
EPS (TTM)-2.1490
Earnings date28 Mar 2022 - 01 Apr 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est11.00
  • Business Wire

    Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference

    LEXINGTON, Mass., May 18, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Scientific Officer Dr. Christopher Loose will present at the upcoming H.C. Wainwright Global Investment Conference.

  • Business Wire

    Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results

    LEXINGTON, Mass., May 04, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced business updates and financial results for the first quarter ended March 31, 2022.

  • Business Wire

    Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference

    LEXINGTON, Mass., April 22, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Scientific Officer Dr. Christopher Loose and Vice President of Discovery Biology Dr. Sanjay Magavi will participate in a fireside presentation at the B. Riley Securities’ Neuro & Ophthalmology Conference on April 28, 2022 at 3:30 pm ET.